UCSF home page UCSF home page About UCSF UCSF Medical Center
UCSF navigation bar
photos

Faculty Profiles

Margaret Tempero, MD
M_MED-CORE-HMON-ONCO-GEN
Professor

550 16th Street
San Francisco, CA 94158
415-353-7528

Dr. Tempero is Director, UCSF Pancreas Center and Leader, Pancreas Cancer Program. Her research career has focused on pancreatic ductal adenocarcinoma especially in the area of investigational therapeutics. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Her group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials. Currently her group is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation.


Dr. Tempero directed the first GI SPORE devoted to pancreatic cancer when she was on the faculty of the University of Nebraska and subsequently led the NCI funded U54 Molecular Target Assessment Team at UCSF. She also organized the first Pancreas Cancer Think Tank in 1999 and co-led the NCI sponsored Progress Review Group on Pancreatic Cancer in 2000. She has served as the Chair of the NCCN Guidelines Panel on Pancreatic Cancer since 2000. She also serves on the Pancreatic Cancer Task Force for the NCI intergroup and recently co-organized the State of the Science meeting on pancreatic cancer at the NCI.


Dr. Tempero also has extensive experience in scientific review and administration, training and oversight. She co-directed the AACR/ASCO Methods in Clinical Cancer Research in Vail for 3 years and spent 9 years of service teaching this course and similar courses in Europe and Australia. She was founding Chair of the NCI Clinical Oncology Study Section (CONC) and served as a member and Chair (2-year term) of the NCI Board of Scientific Counselors Subcommittee A. She is on the External Advisory Boards of the Pancreas SPORE at MDACC and the GI SPOREs at the University of Arizona and Northwestern. She is, or has been, on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board and the EORTC. She has held many appointments at AACR and ASCO and has served as a member of the ASCO Board of Directors and as ASCO President in 2004. She recently served as a member of the Oncology Drug Advisory Committee for the FDA. She served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center until 1999, Chief Emeritus of the Division of Medical Oncology at UCSF (2000 – 2007) and Deputy Director and Director of Research Programs at the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) from 2000 to 2012.

Education and Training

Location Degree or Training Specialty Date
University of Nebraska M.D. School of Medicine 1977

Interests

CA 19-9, Cancer, antibodies, biomarkers, clinical trials, gastrointestinal cancers, gemcitabine, immunotherapy, pancreas, pancreatic adenocarcinoma, practice guidelines, quality of life, radioimmunoconjugate

Awards and Honors
2014   Editor-In-Chief, Journal Nat'l Comprehensive Cancer Network, 2014-Pres
2012   Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science, UCSF, 2012-Pres
2000   Doris and Don Fisher Distinguished Professor in Clinical Research, UCSF, 2000-2012

Related Web Sites

In the News

Recent Articles (148)

Tempero M. Movin' On Up! J Natl Compr Canc Netw. 2018 Jun; 16(6):675.

Tempero M. Getting Into the Weeds. J Natl Compr Canc Netw. 2018 May; 16(5):457.

Tempero M. Standing Together or Alone. J Natl Compr Canc Netw. 2018 Apr; 16(4):341.

Tempero M. Molecular Diagnostics: Another Battle Brewing. J Natl Compr Canc Netw. 2018 Mar; 16(3):225.

Tempero M. Extending Our Reach-Will Telemedicine Get Us There? J Natl Compr Canc Netw. 2018 Feb; 16(2):107.

Tempero M. Revisiting New Year's Resolutions. J Natl Compr Canc Netw. 2018 Jan; 16(1):1.

Tempero M. It's About Time! J Natl Compr Canc Netw. 2017 Dec; 15(12):1443.

Tempero MA. Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Cancer J. 2017 Nov/Dec; 23(6):309.

Tempero M. Who's Watching the Kids? J Natl Compr Canc Netw. 2017 Nov; 15(11):1289.

Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget. 2017 Nov 17; 8(58):97769-97786.

Doherty GJ, Tempero M, Corrie PG. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol. 2018 Jan; 14(1):13-22.

Tempero M. Serving "a la CAR-T": Value-Based Pricing and Gene Therapy. J Natl Compr Canc Netw. 2017 Oct; 15(10):1179.

Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist. 2017 Dec; 22(12):1427-e129.

Tempero M. Your Genes: Getting the Best Fit. J Natl Compr Canc Netw. 2017 Sep; 15(9):1083.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Aug; 15(8):1028-1061.

Tempero M. When It's Really Good, We Know It! J Natl Compr Canc Netw. 2017 Aug; 15(8):973.

Tempero M. Reducing the Cost of Cancer Care: When Less Is More. J Natl Compr Canc Netw. 2017 Jul; 15(7):853.

Tempero M. Getting Practical About Recertification. J Natl Compr Canc Netw. 2017 Jun; 15(6):753.

Tempero M. Active Systemic Treatment of Pancreatic Cancer. J Natl Compr Canc Netw. 2017 May; 15(5S):723-725.

Tempero M. Hospice: Angels at Work. J Natl Compr Canc Netw. 2017 05; 15(5):549.

Tempero M. Politics as Usual-Not! J Natl Compr Canc Netw. 2017 04; 15(4):425.

Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017 04 01; 109(4).

Tempero M. Saying Yes. J Natl Compr Canc Netw. 2017 03; 15(3):277.

Tempero M. Mad About MACRA. J Natl Compr Canc Netw. 2017 02; 15(2):137.

Tempero M. New Year's Resolutions. J Natl Compr Canc Netw. 2017 01; 15(1):1.

van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S. Assessing Researcher Needs for a Virtual Biobank. Biopreserv Biobank. 2017 Jun; 15(3):203-210.

Tempero M. An Oncologist's Letter to Santa. J Natl Compr Canc Netw. 2016 12; 14(12):1491.

Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Grützmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero MA. Hypermutation In Pancreatic Cancer. Gastroenterology. 2017 01; 152(1):68-74.e2.

Tempero M. My Knee Hurts! J Natl Compr Canc Netw. 2016 11; 14(11):1335.

Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 Nov; 45(10):1394-1400.

Tempero M. Crossing the Line. J Natl Compr Canc Netw. 2016 10; 14(10):1191.

Tempero M. Hillary and Donald, Our Patients Are Watching. J Natl Compr Canc Netw. 2016 09; 14(9):1047.

Tempero M. I'll Have Another Shot, Please! J Natl Compr Canc Netw. 2016 08; 14(8):929.

Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016 Oct; 114(5):587-596.

Tempero M. The Greatest Show on Earth! J Natl Compr Canc Netw. 2016 07; 14(7):813.

Tempero M. Did the IRB Approve This? J Natl Compr Canc Netw. 2016 06; 14(6):699.

Tempero M. Closely Guarded Secrets. J Natl Compr Canc Netw. 2016 05; 14(5):487.

Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers. 2016 04 21; 2:16022.

Tempero M. Letting Nature Loose. J Natl Compr Canc Netw. 2016 Apr; 14(4):367.

Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar; 45(3):370-5.

Tempero M. Promising the Moon! J Natl Compr Canc Netw. 2016 Mar; 14(3):237.

Tempero M. Put Us Out of Business--Please! J Natl Compr Canc Netw. 2016 Feb; 14(2):123.

Tempero M. Bringing Biosimilars to the Clinic: What's the Fuss? J Natl Compr Canc Netw. 2016 Jan; 14(1):1.

Tempero M. Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. J Oncol Pract. 2016 Jan; 12(1):29-30.

Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov. 2016 Mar; 6(3):270-85.

Tempero M. Paying Less for High-Value Care--Are You Kidding Me? J Natl Compr Canc Netw. 2015 Dec; 13(12):1453.

Tempero M. At Last: Getting Paid to Think! J Natl Compr Canc Netw. 2015 Nov; 13(11):1297.

Tempero M. Putting an End to It! J Natl Compr Canc Netw. 2015 Oct; 13(10):1167.

Tempero M. Crossing Over. J Natl Compr Canc Netw. 2015 Sep; 13(9):1053.

Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 01; 22(1):61-8.

Tempero M. Move It! J Natl Compr Canc Netw. 2015 Aug; 13(8):939.

Tempero M. Express Scripts? Really? J Natl Compr Canc Netw. 2015 Jul; 13(7):827.

Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8.

Tempero M. Improving Access to Drugs--Big Pharma Comes to the Table. J Natl Compr Canc Netw. 2015 Jun; 13(6):703.

Tempero MA. Multidisciplinary management of pancreatic cancer. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl):700-2.

Tempero M. Reducing costs by changing behavior-really? J Natl Compr Canc Netw. 2015 May; 13(5):499.

Tempero M. Turf war over diagnostic testing. J Natl Compr Canc Netw. 2015 Apr; 13(4):375.

Tempero M. Putting precision medicine on the national agenda. J Natl Compr Canc Netw. 2015 Mar; 13(3):251.

Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015 Feb 26; 518(7540):495-501.

Tempero M. All bundled up! J Natl Compr Canc Netw. 2015 Feb; 13(2):121.

Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20; 33(6):654-6.

Tempero M. Meet the New JNCCN! J Natl Compr Canc Netw. 2015 Jan; 13(1):1.

Tempero M. Happy anniversary! J Natl Compr Canc Netw. 2014 Dec; 12(12):1653.

Tempero M. Bringing science to clinical practice. J Natl Compr Canc Netw. 2014 Nov; 12(11):1495.

Tempero M. Cancer screening: when is the juice worth the squeeze? J Natl Compr Canc Netw. 2014 Oct; 12(10):1359.

Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014 Nov; 27(11):1361-70.

Tempero M. Getting what you pay for: finding value in cancer care. J Natl Compr Canc Netw. 2014 Sep; 12(9):1199.

Tempero M. Incentive-based oncology: unintended consequences? J Natl Compr Canc Netw. 2014 Aug; 12(8):1069.

Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93.

Tempero M. A publicly funded clinical trials network: do we need it? J Natl Compr Canc Netw. 2014 Jul; 12(7):953.

Tempero M. Embracing team-based oncology care. J Natl Compr Canc Netw. 2014 Jun; 12(6):845.

Tempero M. Managing the fruits of our success. J Natl Compr Canc Netw. 2014 May; 12(5):603.

Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.

Tempero M. The changing face of community practice: the new normal. J Natl Compr Canc Netw. 2014 Apr; 12(4):449.

Tempero M. JNCCN going forward. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):301.

Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34.

Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20; 109(4):920-5.

Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013 Jun; 144(6):1316-26.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jun 10; 31(17):2189-204.

Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res. 2013 Feb 01; 19(3):538-40.

Cinar P, Tempero MA. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 2012 Nov-Dec; 18(6):653-64.

Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012 Nov 15; 491(7424):399-405.

Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7.

Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81.

Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):703-13.

Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3.

Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011 Jul; 22(7):1500-6.

Collisson E, Tempero M. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clin Cancer Res. 2011 Jan 15; 17(2):203-5.

Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010 Sep; 8(9):972-1017.

International network of cancer genome projects. Nature. 2010 Apr 15; 464(7291):993-8.

Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7.

Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009 Nov 20; 27(33):5660-9.

Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12.

Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5.

Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74.

Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52.

Tempero MA. How I treat pancreatic ductal adenocarcinoma. J Oncol Pract. 2008 Jan; 4(1):46-7.

Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2007 Nov; 5(10):998-1033.

Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007 Jun; 18 Suppl 7:vii1-vii10.

Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):809-16.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33.

Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2007 Feb; 25(1):85-94.

Hruban RH, Rustgi AK, Brentnall TA, Tempero MA, Wright CV, Tuveson DA. Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res. 2006 Jan 01; 66(1):14-7.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85.

Ko AH, Tempero MA. Systemic therapy for pancreatic cancer. Semin Radiat Oncol. 2005 Oct; 15(4):245-53.

Tempero MA, Behrman S, Ben-Josef E, Benson AB, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW, Melvin WS, Muscarella P, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005 Sep; 3(5):598-626.

Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw. 2005 Sep; 3(5):627-36.

Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9.

Tempero MA. Clinical oncology 2004: the president's report. J Clin Oncol. 2004 Nov 15; 22(22):4437-41.

Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003 Sep 15; 21(18):3402-8.

Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003; 34(2-3):107-16.

Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002 Sep; 2(8):774-9.

Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J Nucl Med. 2002 Jul; 43(7):957-67.

Ko AH, Tempero MA. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep. 2002 May; 4(3):202-12.

Augustine SC, Norenberg JP, Colcher DM, Vose JM, Gobar LS, Dukat VJ, Hohenstein MA, Rutar FJ, Jacobson DA, Tempero MA. Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. J Am Pharm Assoc (Wash). 2002 Jan-Feb; 42(1):93-100.

Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA. A white paper: the product of a pancreas cancer think tank. Cancer Res. 2001 Jun 15; 61(12):4923-32.

Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA, Dukat VJ, Hohenstein MA, Gobar LS, Vose JM. Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. J Nucl Med. 2001 Jun; 42(6):907-15.

DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999 Dec; 117(6):1464-84.

Brand RE, Tempero MA. Pancreatic cancer. Curr Opin Oncol. 1998 Jul; 10(4):362-6.

Tempero MA, Brand R. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1998 May 01; 82(9):1800-1.

Habbe TG, McCowan TC, Goertzen TC, Leveen RF, Culp WC, Tempero MA. Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy. J Vasc Interv Radiol. 1998 Mar-Apr; 9(2):233-9.

Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med. 1997 Apr; 38(4):512-6.

Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, Chiou RK. Radiolabeled iododeoxyuridine: safety evaluation. J Nucl Med. 1996 Apr; 37(4 Suppl):13S-16S.

Sivinski CL, Lindner DJ, Borden EC, Tempero MA. Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons. J Immunother Emphasis Tumor Immunol. 1995 Oct; 18(3):156-65.

Kessinger A, Bishop MR, Anderson JR, Armitage JO, Bierman PJ, Reed EC, Tarantolo S, Tempero MA, Vose JM, Warkentin PI. Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization. J Hematother. 1995 Apr; 4(2):81-4.

Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev. 1994 Mar; 3(2):155-60.

Haga Y, Sivinski CL, Woo D, Tempero MA. Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. Int J Pancreatol. 1994 Feb; 15(1):43-50.

Hirota M, Pour PM, Tempero MA, Chaney WG. Purification and analysis of glycoproteins bearing blood group-A determinants from hamster pancreatic ductal adenocarcinomas. Carcinogenesis. 1992 Oct; 13(10):1829-33.

Joshi SS, Mann SL, Tempero MA, Crouse DA, Stratbucker RA, Quaife MA, Sharp JG. Quantitation of metastatic tumor burden from human colon tumor xenografts using radiolabelled monoclonal antibody 17-A fragments. Tumour Biol. 1992; 13(4):195-206.

Tempero MA, Haga Y, Sivinski C, Steplewski Z, Kay HD, Pour P. Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma. Int J Pancreatol. 1991; 9:125-34.

Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, Kay HD. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. J Clin Oncol. 1990 Dec; 8(12):2019-26.

Tempero MA. Advances in the medical management of advanced gastrointestinal cancers. Curr Opin Oncol. 1990 Aug; 2(4):747-53.

Tempero MA, Nishioka K, Knott K, Zetterman RK. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. Cancer Res. 1989 Nov 01; 49(21):5793-7.

Takiyama Y, Tempero MA, Takasaki H, Onda M, Tsuchiya R, Büchler M, Ness M, Colcher D, Schlom J, Pour PM. Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases. Hum Pathol. 1989 Sep; 20(9):832-8.

Takasaki H, Tempero MA, Uchida E, Büchler M, Ness MJ, Burnett DA, Metzgar RS, Colcher D, Schlom J, Pour PM. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. Int J Cancer. 1988 Nov 15; 42(5):681-6.

Pour PM, Tempero MM, Takasaki H, Uchida E, Takiyama Y, Burnett DA, Steplewski Z. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res. 1988 Oct 01; 48(19):5422-6.

Ness MJ, Pour PM, Tempero MA, Linder J. Immunohistochemistry with monoclonal antibody B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma. Mod Pathol. 1988 Jul; 1(4):279-83.

Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res. 1988 Mar 15; 48(6):1435-8.

Tempero MA, Zetterman RK. Effects of sodium cholate on experimental carcinogenesis and cell proliferation in an excluded colonic segment. J Surg Oncol. 1987 Dec; 36(4):253-8.

Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987 Oct 15; 47(20):5501-3.

Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue. Int J Pancreatol. 1987 Oct-Dec; 2(5-6):349-60.

Uchida E, Tempero MA, Burnett DA, Steplewski Z, Pour PM. Correlative studies on antigenicity of pancreatic cancer and blood group types. Cancer Detect Prev Suppl. 1987; 1:145-8.

Petrie HT, Klassen LW, Tempero MA, Kay HD. In vitro regulation of human lymphocyte proliferation by selenium. Biol Trace Elem Res. 1986 Dec; 11(1):129-46.

Tempero MA, Deschner EE, Zedeck MS. The effect of selenium on cell proliferation in liver and colon. Biol Trace Elem Res. 1986 Aug; 10(2):145-52.

Tempero MA, Pour PM, Uchida E, Herlyn D, Steplewski Z. Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer. Hybridoma. 1986 Jul; 5 Suppl 1:S133-8.

Tempero M. Bile acids, ornithine decarboxylase, and cell proliferation in colon cancer: a review. Dig Dis. 1986; 4(1):49-56.

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.